Sensorion’s SENS-601 strategy signals a sharper bet on larger genetic hearing loss markets
Find out how Sensorion’s SENS-601 regulatory push could reshape GJB2 hearing loss gene therapy and clinical strategy.
Pharma & Biotech
Pharma & Biotech
How Sensorion’s SENS-501 data could reshape gene therapy for congenital hearing loss treatment
Sensorion reports promising gene therapy data for congenital deafness. Discover what it means for hearing loss treatment and future clinical breakthroughs.
Pharma & Biotech
Sarepta’s sirolimus gambit: Can enhanced immunosuppression rescue ELEVIDYS for non-ambulatory Duchenne patients?
Sarepta's ELEVIDYS Cohort 8 targets non-ambulatory Duchenne patients with a sirolimus regimen. What the trial design reveals about the path to label restoration.
Pharma & Biotech
Can Sarepta’s ELEVIDYS redefine Duchenne therapy? Inside the 3-year EMBARK data
Sarepta’s gene therapy ELEVIDYS shows 3-year durability in Duchenne muscular dystrophy. Find out what it means for patients, payers, and global rollout.